Amplia Therapeutics (ASX:ATX) has provided an update on the ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in advanced pancreatic cancer. …
Amplia announces second confirmed complete response in ACCENT trial
June 19, 2025 Australian Biotech
Latest Video
New Stories
-
This debate over US tariffs might be the dumbest in PBS history
July 9, 2025 - - Latest News -
AusBiotech welcomes 27 new members in first half of 2025
July 9, 2025 - - Latest News -
Health spending under increasing pressure, as department looks to offsets
July 9, 2025 - - Latest News -
Consortium established to co-design new telehealth standards
July 8, 2025 - - Latest News -
South Australia expands flu vax availability in response to record outbreak
July 8, 2025 - - Latest News -
MedAdvisor restates focus on US following completion of ANZ business sale
July 8, 2025 - - Latest News -
More companies are exercising their rights, and they are perfectly entitled
July 7, 2025 - - Latest News